Stephani Elliott
Adult Health · Plano, TXNPI 1225640998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 447 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 34.1% of the total. 2025 is the largest year on record at $2,313, 2.7 times the $866 reported in 2021. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$831
- Takeda Pharmaceuticals U.S.A., Inc.$767
- Ardelyx, Inc.$414
- Bristol Myers Squibb$389
- QOL Medical, LLC$335
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,190100%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 124 | $3,150 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $831 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $767 |
| Ardelyx, Inc. | 24 | $414 |
| Bristol Myers Squibb | 24 | $389 |
| QOL Medical, LLC | 15 | $335 |
| Intercept Pharmaceuticals, Inc. | 14 | $297 |
| Phathom Pharmaceuticals, Inc. | 13 | $283 |
| Organon | 26 | $266 |
| Aimmune Therapeutics, Inc. | 9 | $238 |
| Regeneron Healthcare Solutions, Inc. | 10 | $228 |
| Johnson & Johnson | 11 | $223 |
| Sanofi | 8 | $222 |
| Gilead | 12 | $192 |
| Madrigal Pharmaceuticals | 7 | $165 |
| Ferring Pharmaceuticals Inc. | 7 | $143 |
| Novo Nordisk | 2 | $137 |
| Boehringer Ingelheim | 4 | $104 |
| Vivus LLC | 6 | $99 |
| Merck | 4 | $87 |
| Ironwood Pharmaceuticals, Inc | 4 | $85 |
| E.r. Squibb & Sons, L.L.C. | 1 | $73 |
| Celltrion USA Inc. | 3 | $65 |
| Evoke Pharma, Inc. | 4 | $65 |
| Braintree Laboratories, Inc. | 4 | $64 |
| Nestle Healthcare Nutrition Inc. | 4 | $58 |
| Redhill Biopharma Inc. | 3 | $57 |
| Neuraxis, Inc. | 1 | $53 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| Mirum Pharmaceuticals, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Exact Sciences | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,224 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 13 | $15,376 |
| Dexlansoprazole DrDexlansoprazole | 18 | $8,312 |
| Pantoprazole Sodium | 175 | $3,032 |
| Omeprazole | 106 | $2,907 |
| Sucralfate | 56 | $2,603 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 14 | $2,231 |
| Famotidine | 103 | $2,228 |
| Esomeprazole Magnesium | 17 | $1,677 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 11 | $1,354 |
| Colestipol Hcl | 11 | $963 |
| Cholestyramine LightCholestyramine | 13 | $903 |
| Ondansetron OdtOndansetron | 28 | $523 |
| Hydrocortisone | 27 | $299 |
| Metronidazole | 16 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $3,150 | $15,37613 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $143 | $2,23114 claims |
| Braintree Laboratories, Inc.Suflave | $64 | $1,35411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.
Other adult health in Plano
- Cynthia BedellPlano$168K
- Catherine KamauPlano$13K
- Virginia RansomPlano$7K
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.